Zhiwei Cui, Haoyu Sun, Zhishuang Gao, Chao Li, Tingting Xiao, Yibo Bian, Zonghang Liu, Tianhao Gu, Jianan Zhang, Tengyun Li, Qianzheng Zhou, Zhongyuan He, Bowen Li, Fengyuan Li, Zekuan Xu, Hao Xu
BACKGROUND: Imatinib has become an exceptionally effective targeted drug for treating gastrointestinal stromal tumors (GISTs). Despite its efficacy, the resistance to imatinib is common in GIST patients, posing a significant challenge to the effective treatment. METHODS: The expression profiling of TRIM21, USP15, and ACSL4 in GIST patients was evaluated using Western blot and immunohistochemistry. To silence gene expression, shRNA was utilized. Biological function of TRIM21, USP15, and ACSL4 was examined through various methods, including resistance index calculation, colony formation, shRNA interference, and xenograft mouse model...
January 5, 2024: British Journal of Cancer